The ACR and RheumPAC are working to secure an annual allocation of $20 million dedicated to research on arthritis prevention and treatment in the Congressionally Directed Medical Research Program budget.
New ACR/ARP Committee Members Are Ready to Work
Volunteering is a great way to give back and can be truly meaningful. Myriad worthwhile causes exist, so it can be hard to choose among them, but donating time to ACR and ARP committees helps promote rheumatology practice and brings awareness to rheumatic diseases. The College relies on volunteers to help achieve strategic priorities, promote…
ACR Insurance Subcommittee Focuses on Coverage & Reimbursement
On behalf of the ACR, I wish you happiness, prosperity and, above all, good health in this new decade. Now that the holidays are behind us and 2020 has launched, the ACR’s dedicated volunteers and staff are working collaboratively to achieve many ambitious initiatives to ensure the College’s dynamic and bright future. A few weeks…
Seq & Ye Shall Find
I nodded, gravely. I was recently privileged to attend a symposium on eosinophils. I realize that this sounds odd. And it was odd, mainly because I’m not an eosinophil expert. Still, they were in need of someone who knew something about eosinophilic granulomatosis with polyangiitis, so I managed to sneak in through the back door….
Myositis-Specific Antibodies Identified
The idiopathic inflammatory myopathies (IIM) encompass eight categories: 1) dermatomyositis (DM) in adults, 2) juvenile dermatomyositis, 3) amyopathic DM, 4) cancer-associated DM, 5) polymyositis, 6) immune-mediated necrotizing myopathy, 7) inclusion body myositis, and 8) overlap myositis.1 These categories help classify the myopathies based on clinical and histologic features. The incidence of IIM is estimated at…
Denosumab Tied to Infection Risk
NEW YORK (Reuters Health)—The osteoporosis drug denosumab is associated with a higher incidence of serious infections compared with placebo, but the risk is similar to comparator drugs, a systematic review and meta-analysis reveals. Talia Diker-Cohen, MD, PhD, of Tel Aviv University, and colleagues searched the literature through May 2019 for randomized controlled trials of denosumab…
Non-Pharmacological Interventions & Management of RA-Related Fatigue
Often, rheumatoid arthritis (RA) patients struggle with fatigue, and the cause of the fatigue remains unclear. Past research suggests RA-related fatigue may be moderately improved by physical activity. A recent narrative review supports these prior findings, noting that patients also benefit moderately from psychosocial interventions…
4 Tips to Limit Missed Appointments
Predictive data models can be used to identify when patients may miss their appointments, reduce these incidents and increase scheduling efficiency. Here are some tips for the physician practice setting…
RA Patients May Be Less Likely to Discontinue Etanercept Than Other TNF Inhibitors
In a systematic literature review, researchers found that rheumatoid arthritis patients taking etanercept were less likely to discontinue their treatment than patients using any of five other tumor necrosis factor inhibitors…
Novartis, Merck & Allergan Join Those Raising U.S. Drug Prices for 2020
NEW YORK (Reuters)—Novartis AG, Merck & Co Inc. and Allergan Plc. were among companies that raised U.S. prices on more than 100 prescription medicines on Jan. 4, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. That is above the average…
- « Previous Page
- 1
- …
- 207
- 208
- 209
- 210
- 211
- …
- 800
- Next Page »